Want to see IN:MOREPENLAB full AI Analyst Report?
MOREPENLAB Stock Chart & Stats
₹41.99
-₹1.18(-1.56%)
At close: 4:00 PM EST
₹41.99
-₹1.18(-1.56%)
Day’s Range― - ―
52-Week Range₹33.42 - ₹150.80
Previous CloseN/A
Volume3.34M
Average Volume (3M)1.03M
Market Cap
₹63.45B
Enterprise Value₹19.69B
Total Cash (Recent Filing)₹916.99M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)45.1
Beta1.69
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.17%
Share Statistics
EPS (TTM)2.56
Shares Outstanding547,953,700
10 Day Avg. Volume806,638
30 Day Avg. Volume1,027,500
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)1.64
Price to Sales (P/S)1.13
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthMeaningful revenue growth across several years indicates that Morepen has expanded its commercial base and maintained demand for its pharmaceutical offerings. This supports scale benefits, broader market reach, and a stronger platform for sustaining earnings over the next several quarters.
Improved Profitable EarningsThe recovery from the weak 2023 earnings base and continued positive net income demonstrate improved operating performance rather than a single isolated profit. Sustained profitability can support reinvestment, strengthen financial resilience, and provide a foundation for future business development.
Moderate Leverage And Equity SupportA growing equity base combined with moderate overall leverage gives Morepen a relatively stable financial structure. This supports its ability to fund operations and manage business volatility, while lower debt dependence preserves more flexibility for future capital allocation.
Bears Say
Persistent Negative Free Cash FlowPersistent negative free cash flow indicates that accounting earnings are not converting into surplus cash, creating an ongoing cash-burn concern. If this continues, Morepen may have less internally generated funding for investment and greater reliance on financing to support growth.
Recent Debt IncreaseThe material recent increase in total debt weakens the balance sheet relative to the prior year, even though leverage remains moderate overall. Higher debt can reduce financial flexibility and increase the importance of restoring stronger cash generation over the medium term.
Margin Compression And Slower GrowthRecent revenue softness alongside lower operating and net margins suggests that earnings momentum has cooled and profitability is facing pressure. Without renewed growth or margin recovery, this could constrain earnings expansion and reduce the durability of the improved results seen since 2023.
Morepen Laboratories Limited News
MOREPENLAB FAQ
What was Morepen Laboratories Limited’s price range in the past 12 months?
Morepen Laboratories Limited lowest stock price was ₹33.42 and its highest was ₹150.80 in the past 12 months.
What is Morepen Laboratories Limited’s market cap?
Morepen Laboratories Limited’s market cap is ₹63.45B.
When is Morepen Laboratories Limited’s upcoming earnings report date?
Morepen Laboratories Limited’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Morepen Laboratories Limited’s earnings last quarter?
Morepen Laboratories Limited released its earnings results on Aug 04, 2026. The company reported ₹1.029 earnings per share for the quarter.
Is Morepen Laboratories Limited overvalued?
According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued.
Does Morepen Laboratories Limited pay dividends?
Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.17%. See more information on Morepen Laboratories Limited dividends here
What is Morepen Laboratories Limited’s EPS estimate?
Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morepen Laboratories Limited have?
Morepen Laboratories Limited has 547,953,700 shares outstanding.
What happened to Morepen Laboratories Limited’s price movement after its last earnings report?
Morepen Laboratories Limited reported an EPS of ₹1.029 in its last earnings report. Following the earnings report the stock price went up 19.99%.
Which hedge fund is a major shareholder of Morepen Laboratories Limited?
Currently, no hedge funds are holding shares in IN:MOREPENLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Morepen Laboratories Limited
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a diverse range of home healthcare products. Its API portfolio encompasses compounds utilized in the creation of drugs for conditions such as allergies, asthma, elevated cholesterol, hypertension, and diabetes. The company also supplies an array of point-of-care and medical devices for home use, including diagnostic tools like air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse oximeters, nebulizers, glucometers with accompanying strips, as well as hygiene products such as sanitizers, disinfectant solutions, masks, and gloves. Among its well-known branded products are Burnol, a cream for treating burns; Lemolate, an offering for cough and cold relief; and Fiber-X, a psyllium husk supplement. Furthermore, Morepen produces finished drug formulations covering various therapeutic areas, including gastrointestinal health, antibiotics, vitamins, nutritional support, anti-diabetics, and cardiovascular conditions. Beyond these offerings, the company undertakes contract manufacturing for other businesses and participates in brand sharing agreements. Its comprehensive range of over-the-counter (OTC) products is marketed under the recognizable Dr. Morepen brand. The company's global footprint extends to approximately 75 nations, where its products are exported. Established in 1984, Morepen Laboratories Limited maintains its headquarters in New Delhi, India.
Technical Analysis
Alembic Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Solara Active Pharma Sciences Ltd.
―
Windlas Biotech Ltd.
―









